Clinical trials: Hepatitis C, completed
Hepatitis C
EDP-494-001: A Study of EDP-494 in Healthy Subjects and Hepatitis C Patients
This randomized, double-blind study will assess the safety, pharmacokinetics and efficacy of a single and multiple dose(s) of orally QD administered EDP-494 in healthy volunteers (HV) and in treatment-naive subjects with GT1/3…
- Trial name
- NCT02652377
- Testing
- EDP-494
- Where
- New Zealand
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Enanta Pharmaceuticals, Inc
Hepatic Fibrogenesis, Hepatitis C
Impact of Moderate Alcohol Use on Hepatitis C Virus (HCV) Progression
The purpose of this study is to determine the effect of moderate alcohol intake on liver disease caused by HCV in terms of speed of progression as compared to those not drinking alcohol.
- Trial name
- NCT00205075
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- University of Wisconsin, Madison
Hepatitis C
TMC435350-TiDP16-C101 - A Study to Examine the Safety, Tolerability and Pharmacokinetics of Increasing Oral Doses of TMC435350 After Single and Repeated Dosing
The purpose of this study is to examine the safety, tolerability and pharmacokinetics of increasing oral doses of TMC435350 after single and repeated dosing, followed by an open label repeated dosing session in 6 HCV genotype1…
- Trial name
- NCT00938899
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- Tibotec Pharmaceuticals, Ireland
Healthy Volunteers, Hepatitis C Virus
Adaptive Phase I HCV Study With Nucleoside Analogue, in Combination With Interferon and Ribavirin
This is an adaptive Phase I study to evaluate RO5024048 in the following groups: Healthy Volunteers (Part 1 - Single Ascending Dose Study) -Enrollment completed Hepatitis C virus (HCV) genotype 1 infected patients who have failed…
- Trial name
- R7128 (NCT00382798)
- Testing
- RO5024048
- Where
- 9 sites in United States, New Zealand and 1 more
- Volunteers
- 75 people
- Sponsor
- Pharmasset
Hepatitis C
UNITY 1: A Study of an Investigational Treatment Regimen of Daclatasvir (DCV) + Asunaprevir (ASV) + BMS-791325 in a Fixed Dose Combination (the DCV 3DAA (Direct Acting Antiviral) Regimen) for 12 Weeks for the Treatment of Chronic Hepatitis C Virus (HCV) Genotype 1 Infection in Non-cirrhotic Subjects
To demonstrate the effectiveness of DCV 3DAA fixed dose regimen in treatment naive and treatment experienced non-cirrhotic subjects
- Trial name
- NCT01979939
- Testing
- DCV/ASV/BMS-791325
- Where
- 66 sites in United States, Australia and 3 more
- Volunteers
- 416 people
- Sponsor
- Bristol-Myers Squibb
Iron Overload, Metabolic Syndrome X
Quantification of Liver Iron Overload and Steatosis Using Magnetic Resonance Imaging
Iron excess is increasingly regarded as an important cofactor in the morbidity attributed to many disorders. Assessment of body iron stores by measurement of serum ferritin concentrations has poor specificity and the most…
- Conditions
- Iron Overload, Metabolic Syndrome X, Hepatitis B, Hepatitis C
- Trial name
- SURFER (NCT00401336)
- Testing
- Magnetic resonance imaging multiecho gradient-echo sequence
- Where
- 10 sites in France, Spain
- Volunteers
- 250 people
- Sponsor
- Rennes University Hospital
Hepatitis C
A Direct obserVed therApy vs fortNightly CollEction Study for HCV Treatment - ADVANCE HCV Study
Hepatitis C is a blood borne virus that can seriously damage the liver. An estimated 50,000 Scots have been infected with Hepatitis C virus (HCV). The main driver for spread of HCV infection is intravenous drug use.
- Trial name
- ADVANCE (NCT03236506)
- Testing
- Elbasvir/Grazoprevir 50 MG-100 MG Oral Tablet, Psychological intervention, Sofosbuvir 400 MG
- Where
- 2 sites in United Kingdom
- Volunteers
- 129 people
- Sponsor
- University of Dundee
Hepatitis B, Hepatitis C
Long-Term Study of Liver Disease in People With Hepatitis B and/or Hepatitis C With or Without HIV Infection
Background: Hepatitis B and hepatitis C can cause liver damage. They can also cause serious illness, including liver cancer, and even death. This study will follow people who have hepatitis B or hepatitis C.
- Conditions
- Hepatitis B, Hepatitis C, HIV-HCV Co-Infection
- Trial name
- NCT01350648
- Where
- 2 sites in United States
- Volunteers
- 569 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Hepatitis C, Substance Use Disorders
HCV Group Evaluation and Treatment Uptake (HCV GET-UP) Intervention
People who inject drugs (PWID) represent the overwhelming majority of both HCV and HIV/HCV infected people in the United States.
- Trial name
- NCT03242655
- Testing
- HCV GET-Up (Group Evaluation and Treatment Uptake)
- Where
- United States
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- Montefiore Medical Center
Hepatitis C, Hepatitis C, Chronic
Study of AT-527 in Combination With Daclatasvir in Subjects With Hepatitis C Virus (HCV) Infection
The study will assess the safety and efficacy of AT-527 in combination with daclatasvir after 8 or 12 weeks of treatment.
- Conditions
- Hepatitis C, Hepatitis C, Chronic, Chronic Hepatitis C, Hepatitis C Virus Infection
- Trial name
- NCT04019717
- Testing
- AT-527, Daclatasvir
- Where
- 3 sites in Belgium, Mauritius and 1 more
- Volunteers
- 10 people
- Sponsor
- Atea Pharmaceuticals, Inc.
Hepatitis C, HIV Infections
Peginterferon and Ribavirin on Virologic and Immunologic Parameters in Hepatitis C Mono- and Coinfected Patient (PRIVICOP)
Hepatitis C and HIV infect worldwide millions of people leading to a high rate of coinfected patient with eventually liver cirrhosis and endstage liver disease.
- Trial name
- NCT00150904
- Testing
- venous blood puncture
- Where
- Netherlands
- Volunteers
- 28 people
- Sponsor
- UMC Utrecht
Substance Use, HIV Infections
Kentucky Communities and Researchers Engaging to Halt the Opioid Epidemic (CARE2HOPE)
This study will test the effects of an intervention to reduce substance use and related harms among people leaving rural jails or otherwise involved in the criminal justice system.
- Conditions
- Substance Use, HIV Infections, HCV Infection, Sexually Transmitted Infections (Not HIV or Hepatitis)
- Trial name
- NCT04134767
- Testing
- Health Linkage, Overdose Education
- Where
- United States
- Volunteers
- 234 people, healthy volunteers welcome
- Sponsor
- April M Young
Hepatitis C, Chronic, Hepacivirus
Adherence in Patients Receiving PegIntron/Rebetol for Hepatitis C in Conjunction With a Psychotherapy Support Program (Study P04252)
Several psychiatric adverse events (eg, depression, fatigue, psychoses, behavior troubles, anxiety, irritability, deteriorated concentration, and insomnia) that are likely to occur during the treatment course with PegIntron plus…
- Trial name
- NCT00723892
- Testing
- Peginterferon alfa-2b (PegIntron), Rebetol (Ribavirin), Psychotherapy support program
- Volunteers
- 614 people
- Sponsor
- Merck Sharp & Dohme LLC
Hepatitis C and B VIRUS Screening, Awareness and Behavior Assessment and Evaluation for All Inhabitants Above Twelve Years of Al Othmaneya Village
Effect of Implementation Of Outreach Behavioral Change Program for HCV Elimination
Elimination of hepatitis C virus (HCV) is the process of stopping sustained transmission of viral hepatitis, reducing its incidence to zero and providing access to safe, affordable and effective treatment and care for everyone.
- Trial name
- NCT03415334
- Testing
- behavioral development for change
- Volunteers
- 3,575 people, healthy volunteers welcome
- Sponsor
- National Research Centre, Egypt
Hepatitis C, Genotype 3
Interferon-gamma With Interferon Alpha and Ribavirin for Hepatitis C Non-responders
When administered simultaneously, interferon-alpha 2b + interferon-gamma result in dramatic antiviral synergy.Ribavirin has shown to enhance interferon-gamma levels in patients with chronic hepatitis C treated with…
- Conditions
- Hepatitis C, Genotype 3, Non-responders, Relapsers
- Trial name
- NCT00538811
- Testing
- interferon alpha-2b, ribavirin, interferon-gamma,, interferon alpha-2b, ribavirin, amantadine
- Where
- 2 sites in Pakistan
- Volunteers
- 40 people
- Sponsor
- Aga Khan University
Hepatitis C Virus (HCV)
A Study of Glecaprevir (GLE)/Pibrentasvir (PIB) in Treatment-Naive Adults With Chronic Hepatitis C Virus (HCV) Genotype 1-6 Infection and Compensated Cirrhosis
A Phase 3b, single arm, open-label, multicenter study in treatment naïve adults with chronic HCV infection and compensated cirrhosis to assess the safety of 8 weeks of treatment with glecaprevir/pibrentasvir and to demonstrate…
- Trial name
- EXPEDITION-8 (NCT03089944)
- Testing
- Glecaprevir/Pibrentasvir
- Where
- 113 sites in United States, Bulgaria and 17 more
- Volunteers
- 343 people
- Sponsor
- AbbVie
Chronic Kidney Disease, Chronic Hepatitis C
Viekira Pak or Mavyret Treatment for Patient With Chronic Kidney Disease and Hepatitis C
Open-label experimental trial of 12 weeks of Viekira Pak treatment ± ribavirin or Mavyret for adults with chronic kidney disease and hepatitis C.
- Trial name
- NCT02946034
- Testing
- Viekira Pak ± ribavirin, Mavyret
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Massachusetts General Hospital
Hepatitis C
A Study of the Combination Regimen Grazoprevir (MK-5172) and Elbasvir (MK-8742) ± Ribavirin in Participants With Chronic Hepatitis C (MK-5172-035)
This is a study of the safety and efficacy of grazoprevir (MK-5172) in combination with elbasvir (MK-8742) ± ribavirin (RBV). The primary efficacy endpoint will be Sustained Virologic Response 12 weeks after the end of all study…
- Trial name
- C-WORTHy (NCT01717326)
- Testing
- Grazoprevir, Elbasvir, Ribavirin
- Volunteers
- 573 people
- Sponsor
- Merck Sharp & Dohme LLC
Hepatitis C, Chronic
A Study of RO5190591 (Danoprevir) in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Genotype 1 Virus Infection
This 2 part study will evaluate the efficacy and safety of 12 and 24 weeks treatment with RO5190591 (danoprevir) in combination with Pegasys and Copegus, compared to Pegasys and Copegus alone, in treatment-naive patients with…
- Trial name
- NCT00963885
- Testing
- Copegus, Pegasys, RO5190591 (Danoprevir)
- Where
- 43 sites in United States, Australia and 5 more
- Volunteers
- 229 people
- Sponsor
- Hoffmann-La Roche
Chronic Hepatitis C Infection
Sofosbuvir Containing Regimens for the Treatment of Chronic HCV GT3 Infected Patients
The purpose of this study is to assess the safety, tolerability, and efficacy of Sofosbuvir containing regimens in treatment-naive or treatment-experienced patients with HCV genotype 3 infection.
- Trial name
- NCT02576314
- Testing
- sofosbuvir and daclatasvir, ledipasvir/sofosbuvir
- Where
- 2 sites in China
- Volunteers
- 48 people
- Sponsor
- Humanity and Health Research Centre
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.